Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma.

ABSTRACT:

Background

Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years. Accurate assessment of prognosis in high-risk patients would aid in improving outcomes. Here we evaluate the use of circulating tumor DNA (ctDNA) in RCC using banked samples and clinical data from a single institution.

Methods

The cohort consisted of 45 RCC patients (≥pT1b) who underwent complete resection. The presence of ctDNA in plasma was determined using a personalized, tumor-informed ctDNA assay (Signatera RUO, Natera, Inc.). Relationships with outcomes and other relevant clinical variables were assessed. The median follow-up was 62 months.

Results

Plasma ctDNA was detected in 18 out of 36 patients (50%) pre-operatively and w

SUBMITTER: Correa AF 

PROVIDER: S-EPMC11449105 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature